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The explosion in genome sequencing provides a rich
resource for reconstructing the evolutionary origins of gene
families. One proposed application for such phylogenomic
information is to identify highly conserved sequences in
human proteins suspected of being associated with disease,
and to use this information to identify sequence variants in
these regions as potential disease-causing mutations. A
recent example of this approach is a study by Finnerty et al.
of the MSX homeobox family published in BMC Evolu-
tionary Biology [1]. MSX is of particular interest because it
represents one of the most ancient families of animal
homeodomain proteins, and mutations in both paralogous
human genes, MSX1 and MSX2, have been associated with
craniofacial disorders [1,2]. The work by Finnerty et al. [1],
which focuses on the MSX1 sequence changes, provides a
useful case study in the context of current initiatives to
generate large amounts of genomic sequence data from
complex diseases. These will yield thousands of rare
sequence variants, causing headaches for interpretation of
the pathogenicity of individual sequence changes. So, how
successful has the analysis of MSX sequences been in aiding
interpretation of human MSX1 sequence variations?
H Hu um ma an n   M MS SX X: :   e ev vo ol lu ut ti io on n   a an nd d   d do om ma ai in n   o or rg ga an ni iz za at ti io on n
The human genome contains two MSX paralogs, MSX1
located at 4p16.2 and MSX2 at 5q35.2. There is strong
evidence that these genes arose from the second round of
whole-genome duplication that took place at the base of the
vertebrate radiation (the additional two copies expected
from these duplication events have been lost in humans,
but rodents retain an Msx3 gene predicted to have split from
Msx1/Msx2 at the first duplication event).
Apart from the well-known homeodomain (‘MH4’), Finnerty
et al. [1] confirm and extend a recent analysis [3], finding six
other highly conserved sequence elements within human
MSX proteins, which they term MH1N, MH1C, MH2, MH3,
MH5 and MH6 (Figure 1a). The elements MH1N and
MH1C exhibit homology, suggesting that they arose from
an ancient duplication of a Groucho-binding domain;
MH1C has been secondarily lost in MSX2 (and inde-
pendently in rodent Msx3), but is retained in MSX1. MH6
near the carboxyl terminus is a newly identified motif and
represents a PIAS-binding domain. Finnerty et al. [1]
convincingly demonstrate that use of phylogenetically deep
A Ab bs st tr ra ac ct t
A detailed sequence comparison of the MSX homeobox family sheds light on its evolution and
identifies new conserved motifs. But in the absence of corroborative genetic data, phylo-
genomics alone can provide only limited insights into the pathogenicity of heterozygous
missense substitutions in human genes.
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poorly conserved regions of the MSX proteins.
Having undertaken this alignment, sequence changes found
in human MSX1 in samples from patients with either tooth
agenesis or cleft lip/palate (CL/P) were mapped in relation to
the conserved sequence elements, to help predict the severity
of their functional effects [1]. Here I will focus on the
missense changes, as these are the most difficult to interpret,
and ask to what extent these efforts have succeeded.
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Previous linkage studies of segregating Mendelian traits
followed by candidate gene sequencing revealed sequence
26.2 Journal of Biology 2009, Volume 8, Article 26 Wilkie http://jbiol.com/content/8/3/26
Journal of Biology 2009, 8 8: :26
F Fi ig gu ur re e   1 1
MSX1 structure and MAPP evaluation of sequence changes. ( (a a) ) Cartoon of protein [1] showing relative positions of seven conserved motifs (boxes)
and missense substitutions (arrowheads), colored according to whether they have been identified primarily in control samples (black), tooth agenesis
(blue) or CL/P (red). The asterisk indicates that the A219T substitution is only associated with the phenotype in homozygotes. ( (b b) ) MAPP scores for
each substitution, arranged according to evidence for pathogenicity. Dashed lines linking to (a) indicate relative position in the protein for
substitutions found in control and tooth-agenesis samples. Higher MAPP scores indicate a reduced likelihood that a substitution would be tolerated.
Note that the A194V substitution [4] was not included in the MAPP analysis [1].
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(b)changes in MSX1 that are undoubtedly pathogenic; they
show highly significant statistical association with disease
(by segregation through a family) and are associated with a
consistent phenotypic pattern of presentation and high
penetrance. These heterozygous MSX1 mutations character-
istically cause agenesis (loss) of elements of the secondary
dentition, especially the second premolars and third molars.
The phenotype of these missense mutations can be deduced
to be due to haploinsufficiency because dominant muta-
tions that obviously confer loss of function (complete gene
deletions, nonsense and frameshift mutations) give an iden-
tical phenotype.
The positions of the five MSX1 missense mutations that fit
this category (M61K, A194V, R196P, A219T, A221E) as
mapped onto the conserved sequence elements identified
by Finnerty et al. [1] are shown in Figure 1a (blue arrow-
heads). They are all located within the most highly con-
served regions of the protein (one in the MH1N domain
and four in the homeodomain) and collectively exhibit very
high disease penetrance for tooth agenesis (29 of 31 with
the relevant mutant genotype); none of these individuals
had CL/P. So far, so good: the molecular predictions appear
to agree with the genetics. However, two important caveats
should be noted. First, in the report of the A194V mutation
[4], only one of the three heterozygotes studied had any
dental abnormality, indicating that this particular substi-
tution is associated with incomplete penetrance [4]. Second,
in the report of the A219T mutation, only homozygous
individuals exhibited dental abnormalities (five of five
individuals); none of the eight heterozygotes identified had
any dental manifestations [5]. This suggests that the
particular missense alleles A194V and A219T confer only
partial loss of function, to different extents - that is, they are
hypomorphs - and it illustrates an important limitation to
the type of in silico analysis carried out by Finnerty et al. [1].
Simply demonstrating that a sequence change is likely to be
disruptive is an insufficient criterion for disease causation,
as it does not predict whether (and in what proportion of
individuals) that change will produce a disease phenotype
when present in the heterozygous state. Only empirical
genetic analysis can answer that question.
S Se eq qu ue en nc ce e   v va ar ri ia at ti io on n   i in n   h hu um ma an n   M MS SX X1 1: :   c cl le ef ft t   l li ip p/ /p pa al la at te e   i in n
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In contrast to the demonstrated Mendelian inheritance of
MSX1 defects in tooth agenesis, the association of muta-
tions in MSX1 with human CL/P are based on genetic data
that are much less robust for each individual sequence
variant. Prompted by the clefting phenotype in Msx1-/- mice
[6] and by the occurrence of CL/P associated with a hetero-
zygous S105X mutation in four out of twelve members of a
family segregating tooth agenesis [7], several groups have
undertaken DNA sequencing of large numbers of CL/P cases
and compared these with control samples. These studies
yielded rare heterozygous missense changes in around 1%
of cases [8], prompting claims that MSX1 mutations are an
important ‘cause’ of CL/P. Importantly, none of the variants
identified resides within the MH1N or homeodomain
regions harboring the tooth-agenesis mutations; rather, they
locate to other regions of the protein, some in the remain-
ing conserved motifs described above, and some outside
them (Figure 1a, red arrowheads).
On the basis of the MSX phylogenomic analysis, Finnerty et
al. [1] attempted to analyze the pathogenicity of each of
these variants individually, as judged by the degree of
sequence conservation at their location and thus the
potential effect of the mutation on protein structure and
function. Several considerations indicate that this exercise
will be problematic. In contrast to the tooth-agenesis muta-
tions, none of the CL/P variants has presented in a pedigree
showing clear Mendelian inheritance: at best, some familial
clustering is observed, suggesting a more complex causation
involving multiple genetic and/or environmental factors. In
cases with available parental samples, one parent has always
been found to harbor the same variant, even when they are
unaffected themselves. Most of these variants have been
identified in only single CL/P cases, making the task of
obtaining a statistically robust distinction from controls
formidably difficult (if 1 variant is found in 100 affected
cases, it must be absent from 1,900 controls to obtain a P-
value for the difference of 0.05). In the two instances where
the variants have been discovered in multiple affected
samples (E78V and P147Q), they have also turned up in
control sample(s) from ethnically matched populations.
The most direct way to estimate the penetrance of CL/P
associated with these variants would be to trace them back
through the proband’s family and ask what proportion of
heterozygotes was affected. However, few such cascaded
family studies have been undertaken. Where they have been
performed (for example, in the cases of the G116E [8] and
P147Q [9] variants) the correlation with phenotype has
been poor, with the variant absent in some affected family
members and present in some unaffected members. In this
difficult context, can phylogenomic analysis help to sort out
which of these sequence changes may be conferring a higher
liability for CL/P than others?
I In nt te er rp pr re et ti in ng g   p pa at th ho og ge en ni ic ci it ty y   f fr ro om m   s se eq qu ue en nc ce e
c co on ns se er rv va at ti io on n   a an nd d   p pr ro ot te ei in n   m mo ot ti if fs s   
Finnerty  et al. [1] examined the impact of amino acid
changes in human MSX1 using the multivariate analysis of
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ates pathogenicity on the basis of both sequence conser-
vation at the substituted position and the comparative
physicochemical properties of the wild-type and substituted
amino acids. MAPP analysis was performed at three differ-
ent depths of sequence conservation, human-amniote,
human-tetrapod and human-cnidarian [1]. Although MAPP
is not the only method for undertaking this type of analysis,
it is unlikely that choice of a different algorithm would have
substantially altered the conclusions.
Combining the MAPP analysis with the location of
sequence changes relative to the conserved elements,
Finnerty et al. [1] concluded that several of the CL/P variants
were likely to be disease alleles. They further proposed that
the different MSX1 mutant phenotypes are related to
whether the sequence changes occur in regions functionally
redundant with MSX2. From this viewpoint, mutations in
the highly conserved MH1N and MH4 regions cause ‘mild’
phenotypes because MSX2 can partially replace these roles;
by contrast, mutations outside these regions (the amino
terminus excepted) cause ‘strong’ CL/P phenotypes because
they affect the nonredundant functions of MSX1 (for
example, those involving the MH1C domain). The authors
further proposed that the CL/P variants are acting as
dominant-negatives. Although ingenious, this explanation
is not entirely convincing. From the genetic evidence the
CL/P variants are not dominant negative - they are neither
simple dominants, nor associated with the same phenotype
as loss-of-function mutation. Nor do they preferentially occur
in the conserved regions with functions supposedly distinct
to MSX1 (Figure 1a). An equally plausible interpretation is
that the location of the CL/P variants simply reflects avoi-
dance of the most highly conserved parts of MSX1, and that
they represent a bunch of susceptibility alleles of varying
degrees of weakness, which sometimes act in concert with
other genetic/environmental factors to disrupt palatogenesis.
One can evaluate the limitations of MAPP analysis in this
type of situation by regrouping the results of the analysis of
Finnerty et al. (given in Figure 7 of [1]) according to the
phenotype with which the sequence change has been
associated, and according to the strength of the genetic
evidence supporting the association (Figure 1b). The only
consistent feature in these three analyses is that the four
tooth-agenesis mutations examined have high MAPP scores,
indicating that the amino acid position affected is highly
conserved and the altered residue is therefore likely to be
deleterious. Note, however, that the recessive A219T sub-
stitution is indistinguishable at all three evolutionary levels
from the other, dominantly transmitted, changes. Turning
to the other missense substitutions, no trends are apparent.
There is substantial variation in MAPP scores both within
and between categories, and the most consistently high set
of scores concern a sequence change, G16D, that was
observed in controls [8] rather than CL/P samples (Figure 1a,
black arrowhead). This inconsistency indicates that the
ability of MAPP analysis to predict the penetrance of
different heterozygous sequence changes associated with
CL/P is likely to be poor.
T Th he er re e’ ’s s   n no o   s su ub bs st ti it tu ut te e   f fo or r   g go oo od d   g ge en ne et ti ic c   s st tu ud di ie es s! !
Ultimately, the interpretation of the data on MSX1 muta-
tions in CL/P [1] is undermined by the key consideration
that we cannot easily know what the consequence of a
missense change - that might be obviously pathogenic in
the homozygous state - will be in the heterozygous state. We
need a framework in order to make such interpretations, as
we have in the case of the Mendelian condition of tooth
agenesis. Here, we can conclude, by genetic and
comparative arguments, that certain mutations cause
complete or partial loss of function. Such a framework is
currently missing for these CL/P variants.
So, are phylogenomic comparisons of no use in interpreting
disease-associated mutations? Of course this is not the case;
I frequently use such evaluations in my own work on
Mendelian mutations. But the difficulties become much
greater when attempting to understand the significance of
rare variants in common complex disease. Ultimately, the
only sure way to interpret the disease burden associated
with these CL/P variants will be to undertake much larger
case-control studies, and to ensure that thoroughly cascaded
family follow-up is performed on those rare sequence
changes that are encountered.
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